ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1077

Mediation of Adverse Pregnancy Outcomes in Autoimmune Conditions by Pregnancy Complications

Christina Chambers1, Gretchen Bandoli 2, Namrata Singh 3, Jennifer Strouse 4, Rebecca Baer 5, Brittney Donovan 6, Sky Feuer 7, Nichole Nidey 6, Kelli Ryckman 6 and Laura Jelliffe-Pawlowski 7, 1University of California San Diego, La Jolla, 2University of California, San Diego, La Jolla, 3University of Iowa, Iowa City, 4University of Iowa Hospitals and Clinics, Iowa City, 5UCSD, La Jolla, 6UIOWA, Iowa City, 7UCSF, San Francisco

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: autoimmune diseases, pregnancy and pregnancy complications

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Session Title: Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Autoimmune conditions are associated with an increased risk of adverse pregnancy complications and outcomes, suggesting that pregnancy complications may mediate the excess risk. We performed a causal mediation analysis to quantify the mediated effects of autoimmune conditions on adverse pregnancy outcomes.

Methods: We queried a retrospective California birth cohort created from linked birth certificates and hospital discharge summaries. From 2,963,888 births, we identified women with rheumatoid arthritis, systemic lupus erythematosus, psoriasis and inflammatory bowel disease. Pregnancy complications included preeclampsia/hypertension, gestational diabetes and infection in pregnancy. Adverse pregnancy outcomes were preterm birth, cesarean delivery and small for gestational age. We performed a causal mediation analysis to estimate the total effects of each autoimmune condition and adverse pregnancy outcome, and the indirect effects of each pregnancy complication.

Results: Each autoimmune condition was associated with an increased risk of all adverse pregnancy outcomes (Tables 1-3, inflammatory bowel disease not shown), except psoriasis and small for gestational age. The strongest mediator was preeclampsia/hypertension, accounting for 20-30% of the excess risk of preterm births and 10-15% of excess cesarean deliveries in all autoimmune conditions except IBD. Gestational diabetes and infections generally accounted for < 10% of excess adverse pregnancy outcomes. Of the four autoimmune conditions, selected pregnancy complications mediated the least amount of adverse pregnancy outcomes among women with inflammatory bowel disease (not shown).

Conclusion: We found evidence that some excess risk of adverse pregnancy outcomes is mediated through pregnancy complications, particularly preeclampsia/hypertension. Quantifying excess risk and associated pathways provides insight into the underlying etiologies of adverse pregnancy outcomes and can inform intervention strategies.


Table 1

Effect decomposition of the influence of rheumatoid arthritis and potential mediators on adverse pregnancy outcomes in 3 million live births in the state of California


Table 2

Effect decomposition of the influence of systemic lupus erythematosus and potential mediators on adverse pregnancy outcomes in 3 million live births in the state of California


Table 3

Effect decomposition of the influence of psoriasis and potential mediators on adverse pregnancy outcomes in 3 million live births in the state of California


Disclosure: C. Chambers, AbbVie, 2, Amgen Inc., 2, Apotex, 2, Barr Laboratories, Inc., 2, Bristol-Myers Squibb, 2, Celgene, 2, GlaxoSmithKline, 2, Janssen Pharmaceuticals, 2, Kali Laboratories, Inc., 2, Pfizer, Inc., 2, Hoffman La Roche-Genentech, 2, Sandoz Pharmaceuticals, 2, Genzyme Sanofi-Aventis, 2, Takeda Pharmaceutical Company Limited, 2, UCB, USA, 2, Gerber Foundation, 2, Teva Pharmaceutical Industries Ltd., 2; G. Bandoli, None; N. Singh, None; J. Strouse, None; R. Baer, None; B. Donovan, None; S. Feuer, None; N. Nidey, None; K. Ryckman, None; L. Jelliffe-Pawlowski, None.

To cite this abstract in AMA style:

Chambers C, Bandoli G, Singh N, Strouse J, Baer R, Donovan B, Feuer S, Nidey N, Ryckman K, Jelliffe-Pawlowski L. Mediation of Adverse Pregnancy Outcomes in Autoimmune Conditions by Pregnancy Complications [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/mediation-of-adverse-pregnancy-outcomes-in-autoimmune-conditions-by-pregnancy-complications/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mediation-of-adverse-pregnancy-outcomes-in-autoimmune-conditions-by-pregnancy-complications/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences